MAIA Biotechnology, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
MAIA Biotechnology, Inc. (MAIA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $44.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-23
- MAIA Biotechnology, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $44.00K, a 131.58% increase from fiscal 2024.
- MAIA Biotechnology, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $19.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-12-31 | $44.00K 10-K · filed 2026-03-23 |
| 2024-12-31 | $19.00K 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |